Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study

Ruchlemer, R., Ben-Ami, R., Bar-Meir, M., Brown, J. R., Malphettes, M., Mous, R., Tonino, S. H., Soussain, C., Barzic, N., Messina, J. A., Jain, P., Cohen, R., Hill, B., Mulligan, S. P., Nijland, M., Herishanu, Y., Benjamini, O., Tadmor, T., Okamoto, K., Arthurs, B., Gottesman, B., Kater, A. P., Talha, M., Eichhorst, B., Korem, M., Bogot, N., De Boer, F., Rowe, J. M. & Lachish, T., Dec-2019, In : Mycoses. 62, 12, p. 1140-1147 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard


  • Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

    Final publisher's version, 652 KB, PDF document

    Request copy


  • Rosa Ruchlemer
  • Ronen Ben-Ami
  • Maskit Bar-Meir
  • Jennifer R. Brown
  • Marion Malphettes
  • Rogier Mous
  • Sanne H. Tonino
  • Carole Soussain
  • Noelie Barzic
  • Julia A. Messina
  • Preetesh Jain
  • Regev Cohen
  • Brian Hill
  • Stephen P. Mulligan
  • Marcel Nijland
  • Yair Herishanu
  • Ohad Benjamini
  • Tamar Tadmor
  • Koh Okamoto
  • Benjamin Arthurs
  • Batsheva Gottesman
  • Arnon P. Kater
  • Munir Talha
  • Barbara Eichhorst
  • Maya Korem
  • Naama Bogot
  • Fransien De Boer
  • Jacob M. Rowe
  • Tamar Lachish

Background Invasive fungal diseases (IFD) are life-threatening infections most commonly diagnosed in acute leukaemia patients with prolonged neutropenia and are uncommonly diagnosed in patients with lymphoproliferative diseases. Objectives Following the initial report of aspergillosis diagnosed shortly after beginning ibrutinib for chronic lymphocytic leukaemia, a survey was developed to seek additional cases of IFD during ibrutinib treatment. Methods Local and international physicians and groups were approached for relevant cases. Patients were included if they met the following criteria: diagnosis of chronic lymphocytic leukaemia/non-Hodgkin lymphoma; proven or probable IFD; and ibrutinib treatment on the date IFD were diagnosed. Clinical and laboratory data were captured using REDCap software. Result Thirty-five patients with IFD were reported from 22 centres in eight countries: 26 (74%) had chronic lymphocytic leukaemia. The median duration of ibrutinib treatment before the onset of IFD was 45 days (range 1-540). Aspergillus species were identified in 22 (63%) of the patients and Cryptococcus species in 9 (26%). Pulmonary involvement occurred in 69% of patients, cranial in 60% and disseminated disease in 60%. A definite diagnosis was made in 21 patients (69%), and the mortality rate was 69%. Data from Israel regarding ibrutinib treated patients were used to evaluate a prevalence of 2.4% IFD. Conclusions The prevalence of IFD among chronic lymphocytic leukaemia/non-Hodgkin lymphoma patients treated with ibrutinib appears to be higher than expected. These patients often present with unusual clinical features. Mortality from IFD in this study was high, indicating that additional studies are urgently needed to identify patients at risk for ibrutinib-associated IFD.

Original languageEnglish
Pages (from-to)1140-1147
Number of pages8
Issue number12
Publication statusPublished - Dec-2019


  • Aspergillus species, CLL, CNS, Cryptococcus species, Ibrutinib, immune-compromised host, invasive fungal diseases, NHL, INFECTIONS, ASPERGILLOSIS, EPIDEMIOLOGY, MALIGNANCIES, MONOTHERAPY, PNEUMONIA, SINUSITIS, THERAPY, RISK

ID: 103398120